A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

Excluded: KEAP1 nonsense mutation

KEAP1 nonsense mutation (any position)

Excluded: KEAP1 frameshift mutation

KEAP1 frameshift mutation (any position)

Allowed: NFE2L2 mutation

with or without nuclear factor erythroid 2-related factor 2 (NRF2 [NFE2L2]) and/or cullin 3 (CUL3) mutations

Allowed: CUL3 mutation

with or without nuclear factor erythroid 2-related factor 2 (NRF2 [NFE2L2]) and/or cullin 3 (CUL3) mutations

Allowed: EGFR activating mutation

Participants with a known driver mutation, including activating epidermal growth factor receptor mutations ... should have progressed after appropriate targeted treatment

Allowed: ALK rearrangement

Participants with a known driver mutation, including ... anaplastic lymphoma kinase rearrangements, should have progressed after appropriate targeted treatment

Allowed: HER2 (ERBB2) overexpression

Participants with known human epidermal growth factor receptor 2 overexpression should have progressed after appropriate targeted treatment

Must have received: standard-of-care therapies — metastatic

Have progressed on or after all prior standard-of-care therapies for metastatic disease

Must have received: platinum-based chemotherapy — metastatic

must be refractory to or have progressed on or after a platinum-based doublet regimen

Must have received: immune checkpoint inhibitor — metastatic

must be refractory to or have progressed on or after ... an immune checkpoint inhibitor

Must have received: anti-EGFR therapy — metastatic

must have received prior treatment with ... an anti-epidermal growth factor receptor agent

Cannot have received: anti-epileptic medications

Current or prior treatment with anti-epileptic medications for the treatment or prophylaxis of seizures